Source comparison
Tesamorelin + Ipa vs Other Growth Hormone Secretagogue Stacks
Not all GH secretagogue combinations are mechanistically equivalent. The table below compares Tesamorelin + Ipa to other commonly researched peptide stacks, focusing on receptor targets, side effect profiles, and typical research applications. Tesamorelin + Ip
This comparison does not assign a generated winner or score.
- Not all GH secretagogue combinations are mechanistically equivalent. The table below compares Tesamorelin + Ipa to other commonly researched peptide stacks, focusing on receptor targets, side effect profiles, and typical research applications.
- Tesamorelin + Ipamorelin
- GHRH-R + GHS-R1a
- 8–10× baseline
- Minimal (< 5% above baseline)
- Visceral fat reduction, body recomposition, metabolic studies
- Gold standard for selective GH amplification without HPA axis disruption—most cited in clinical literature
- CJC-1295 (DAC) + Ipamorelin
- 6–9× baseline (sustained over 7–14 days)
- Minimal
- Long-duration protocols requiring less frequent dosing
- Extended half-life (DAC modification) offers convenience but may blunt pulsatile rhythm—some researchers prefer pulsatile over tonic GH elevation
- Sermorelin + GHRP-6
- GHRH-R + GHS-R1a (+ ghrelin release)
- 5–8× baseline
- Moderate (15–25% cortisol increase)
- Older protocols, appetite stimulation studies
- GHRP-6 stimulates appetite and raises cortisol/prolactin—useful when ghrelin effects are desired but problematic for lean mass focus
- Tesamorelin monotherapy
- GHRH-R only
- 3–4× baseline
- FDA-approved context (HIV lipodystrophy), conservative GH elevation
- Effective but lacks somatostatin suppression—GH pulses shorter in duration
- Ipamorelin monotherapy
- GHS-R1a only
- 2–3× baseline
- Mild GH elevation, sleep quality research
- Safest side effect profile but lower magnitude—often underdosed when used alone
- Here's the honest answer: if your research objective requires maximal GH secretion with minimal off-target effects, Tesamorelin + Ipa is the combination most supported by peer-reviewed literature. CJC-1295 with DAC offers dosing convenience but sacrifices the natural pulsatile rhythm that many researchers consider physiologically superior. GHRP-6 is outdated—its appetite stimulation and cortisol elevation create confounding variables in metabolic studies. Real Peptides also supplies CJC1295 Ipamorelin 5MG 5MG for researchers comparing DAC vs non-DAC formulations, and Sermorelin for those replicating earlier protocol designs.